Frontlight ResearchEarly access
CompletedNo phase
Metabolomics of Obstructive Sleep Apnea
Key facts
- Who runs it
- University of Pennsylvania
- Where
- Philadelphia, United StatesSee the siteAlso in 1 other country, 1 site
- Trial code
- Status
- Completed
- People taking part
- 388 people enrolled
- Started
- 29 Sept 2020
- Ended
- 12 Sept 2025
- Type of study
- Observational
- Record updated
- 14 May 2026
Who can take part
- Age
- 30 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, aged 30-75 years old
- In good general health as evidenced by medical history and diagnosed with Obstructive Sleep Apnea (defined as AHI>5)
- Ability to use accelerometer, perform Type 2 sleep test at home and agree to use PAP treatment
- For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation
Who cannot take part
- Current drug or alcohol abuse
- Known allergic reactions to components of the plastic (used in PAP mask)
- Febrile illness within 2 weeks of signing consent
- Known diagnosis and treatment of diabetes because this will independently alter metabolomic results
- Presence of active cancer treatment or heart failure (ejection fraction <40%)
- Previously drawn laboratory Hemoglobin A1C above normal range (indicative of diabetes)
- Current use of PAP treatment or mandibular advancement device or INSPIRE device
- Pregnancy or lactation
Where in United States
Also in 1 other country, 1 site
- University of PennsylvaniaPhiladelphia, United States
About the trial
What the trial wants to find out
This is an R01 funded project that focuses on the utility of metabolomics as a biomarker for OSA. Aims 1 and 3 leverages banked samples previously collected from subjects with and without OSA at the University of Pennsylvania and University of Iceland. Aim 2 is a prospective study that will collect serum samples from OSA subjects at the University of Pennsylvania and the University of Iceland.
The group in the trial
- Subjects with OSA
Female and male subjects with Obstructive Sleep Apnea (OSA) (AHI \>5)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 14 May 2026